Atopic Dermatitis: Exploring Arctiin as a Potential Treatment Option

Atopic dermatitis (AD), commonly known as eczema, is a chronic inflammatory skin condition that affects up to 3% of adults and 20% of children worldwide. It’s characterized by intense itching, sleep disturbances, and a significant impact on overall quality of life.

Current AD treatments, such as corticosteroids and calcineurin inhibitors, come with side effects like skin atrophy and cancer risk. Emerging therapies like dupilumab and Janus kinase inhibitors are effective but costly and require long-term use. This emphasizes the need for new, safe, and long-term treatment solutions.

Arctii: A Promising Candidate?

Enter Arctii (Fructus arctii), a traditional herbal remedy with anti-inflammatory, anti-allergic, and antioxidant properties.

Arctiin (ARC) is the active ingredient behind Arctii’s therapeutic effects. It possesses numerous biological activities, including anti-inflammatory, anti-allergic, anti-cancer, anti-bacterial, and anti-platelet, and functions as a calcium antagonist.

Potential Benefits for AD

Studies show ARC significantly reduces IgE-mediated reactions and anaphylactic shock caused by compound 48/80. Its anti-inflammatory effects come from inhibiting the NF-κB pathway and reducing inflammatory molecules like IL-6, IL-1β, and TNF-α.

Research suggests Arctiin’s potential to alleviate AD symptoms:

Here we explore its effects on AD in Balb/c mice and HaCat cells stimulated by TNF-α